MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2024 International Congress

    The development of an electronic motor symptoms diary for Parkinson’s disease using qualitative patient insights

    B. Byrom, M. Pereira, P. Reksoprodjo, L. Fredane, R. Hauser (Blue Bell, USA)

    Objective: To develop an electronic version of the Hauser diary, commonly used in clinical trials to assess motor fluctuations and dyskinesia in patients with Parkinson’s…
  • 2024 International Congress

    Correlation Between Sleep and Quality of Life in People With Parkinson’s Disease Treated With Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa

    I. Malaty, O. Vaou, R. Hauser, B. Bergmans, P. Odin, M. Shah, L. Bergmann, L. Harmer, R. Gupta, K. Chaudhuri (Gainesville, USA)

    Objective: To assess the correlation between sleep and quality of life (QoL) in people with Parkinson’s disease (PwP) receiving either oral levodopa/carbidopa immediate-release (LD/CD-IR) tablets…
  • 2024 International Congress

    Opicapone as First-Line Strategy for the Treatment of Wearing-off in Patients with Parkinson’s Disease

    J. Ferreira, J. Lee, H. Ma, B. Jeon, W. Poewe, A. Antonini, F. Stocchi, D. Rodrigues, M. Fonesca, J. Rocha, G. Castilla-Fernández, J. Holenz, O. Rascol (Lisbon, Portugal)

    Objective: The Korean and European ADOPTION studies aimed to explore the efficacy of opicapone (OPC) 50 mg versus an additional 100 mg levodopa dose to…
  • 2024 International Congress

    A matching-adjusted indirect comparison of efficacy and safety for safinamide versus rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease

    Y. Tan, Q. Wei, P. Xu, E. Tao, L. Wang, C. Cattaneo, H. Shang, S. Chen (Shanghai, China)

    Objective: To compare  efficacy and safety of safinamide and rasagiline as adjunctive treatment to levodopa in Chinese patients with Parkinson’s disease (PD) by matching-adjusted indirect…
  • 2024 International Congress

    Motor Phenotype Changes over time in Parkinson’s Disease. A 5-year Follow-up Study

    MF. Valero García, E. Bargay Pizarro, I. Legarda Ramirez, B. Vives Pastor, L. Núñez Santos, S. Jesus Maestre, M. Cosgaya, J. Garcia Caldentey, N. Caballol, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, C. Borrué, B. Solano Vila, M. álvarez Saúco, L. Vela, S. Escalante, E. Cubo, JC. Martínez Castrillo, P. Sánchez Alonso, MG. Alonso Losada, N. López Ariztegui, I. Gastón, J. Kulisevsky, M. Seijo Martinez, C. Ordás, P. Martinez-Martin, P. Mir, D. Santos-García (Palma de Mallorca, Spain)

    Objective: The objectives of this study are to describe the prevalence of different motor phenotypes (MP) in a cohort of Parkinson’s Disease (PD) patients, to…
  • 2024 International Congress

    Developing a selection framework for digital measures of Parkinson’s disease progression for the EJS ACT-PD trial

    R. Ellis-Doyle, ML. Zeissler, C. Gonzalez-Robles, M. Bartlett, S. Collins, S. Del-Din, S. Haar, M. Hu, A. Jha, C. Lambert, A. Noyce, R. Petty, K. Pushparatnam, L. Rochester, C. Siu, G. Mills, A. Schrag, T. Foltynie, C. Carroll, A. Yarnall (London, United Kingdom)

    Objective: To develop a selection process for digital measures (DMs) to include as exploratory outcome measures of Parkinson’s disease (PD) progression in a platform disease…
  • 2024 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, G. Respondek, A. Monnet, N. Shariati, L. Rutten-Jacobs, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (Basel, Switzerland)

    Objective: To evaluate the effect on slowing motor progression and the safety of prasinezumab, a humanized monoclonal antibody targeting aggregated alpha-synuclein, in individuals with early…
  • 2024 International Congress

    Mortality Rate, Cause of Death and Factors Associated with Mortality in Late Stage Parkinson’s Disease

    K. Rosqvist, P. Odin (Lund, Sweden)

    Objective: The aim was to carry out a long-term follow-up of a cohort of patients in late stage Parkinson’s disease (PD) with focus on mortality…
  • 2024 International Congress

    Formulations and Assessments of Intra-nasal noses to brain curcumin delivery using reversible nanoparticles for Parkinsonism treatment: A Preclinical Approach

    S. Jain (Gandhinagar, India)

    Objective: Parkinson's disease (PD) is a prevalent neurological illness that is typified by bradykinesia, postural instability, tremor, and stiffness. An increasing body of research suggests…
  • 2024 International Congress

    Oropharyngeal Adverse Events in Parkinson’s Patients with Motor Fluctuations Treated with Apomorphine Sublingual Film

    L. Wojtecki, F. Moreira, E. Cubo, M. Fonseca, G. Harrison-Jones, C. Denecke Muhr (Düsseldorf, Germany)

    Objective: This post-hoc analysis of Study CTH-301 assessed the occurrence of oropharyngeal treatment-emergent adverse events (TEAEs) in patients with Parkinson’s disease included in this study.…
  • « Previous Page
  • 1
  • …
  • 243
  • 244
  • 245
  • 246
  • 247
  • …
  • 553
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley